AGY — Allergy Therapeutics Share News
0.000.00%
- £393.23m
- £416.07m
- £55.20m
REG - ZQ Capital Limited Allergy Therapeutics - Statement Regarding Possible Mandatory Cash Offer
AnnouncementREG - Allergy Therapeutics - £40.75 million Facility with Equity Financing
AnnouncementREG - Allergy Therapeutics - Trading and Business Update
AnnouncementREG - Allergy Therapeutics - Publication of Interim Results Delayed
AnnouncementREG - Allergy Therapeutics - Patients dosed in VLP Peanut PROTECT trial
AnnouncementREG - Allergy Therapeutics - Block Listing Interim Review
AnnouncementRCS - Allergy Therapeutics - PDMR Dealing
AnnouncementREG - Allergy Therapeutics - Result of AGM
AnnouncementREG - Allergy Therapeutics - Half-Year Trading Update 2023
AnnouncementREG - Allergy Therapeutics - NOTICE OF 2022 ANNUAL GENERAL MEETING
AnnouncementREG - AIM Allergy Therapeutics - Suspension - Allergy Therapeutics plc
AnnouncementREG - Allergy Therapeutics - Price Monitoring Extension
AnnouncementREG - Allergy Therapeutics - Second Price Monitoring Extn
AnnouncementREG - Allergy Therapeutics - Second Price Monitoring Extn
AnnouncementREG - Allergy Therapeutics - Price Monitoring Extension
AnnouncementREG - Allergy Therapeutics - Annual Report and Accounts Delayed
AnnouncementREG - Allergy Therapeutics - Director Resignation
AnnouncementREG - Allergy Therapeutics - Key updates on Grass MATA MPL and VLP Peanut
AnnouncementREG - Allergy Therapeutics - Appointment of Non-Executive Directors
Announcement